Adeno Associated Virus Aav Vector Based Gene Therapy Market

ID: MRFR/HC/27946-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Research Report: Size, Share, Trend Analysis By Disease Type (Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology), By Vector Serotype (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9), By Administration Route (Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Adeno Associated Virus Aav Vector Based Gene Therapy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)25.68%
2024 Market Size$ 5.72 Billion
2025 Market Size$ 7.19 Billion
2035 Market Size$ 70.67 Billion
Key Players
Spark Therapeutics
Bayer AG
Novartis AG
Bristol-Myers Squibb
GSK
Pfizer Inc.
Trends
  • Increased Investment in Research and Development
  • Emergence of Personalized Medicine
  • Regulatory Advancements and Support
Opportunities
  • Regulatory Support for Gene Therapies
  • Rising Prevalence of Genetic Disorders
  • Growing Investment in Biopharmaceuticals
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Disease Type (USD Billion)
      1. 4.1.1 Hematological Malignancies
      2. 4.1.2 Neurological Disorders
      3. 4.1.3 Cardiovascular Diseases
      4. 4.1.4 Ophthalmic Diseases
      5. 4.1.5 Oncology
    2. 4.2 Healthcare, BY Vector Serotype (USD Billion)
      1. 4.2.1 AAV1
      2. 4.2.2 AAV2
      3. 4.2.3 AAV5
      4. 4.2.4 AAV6
      5. 4.2.5 AAV8
      6. 4.2.6 AAV9
    3. 4.3 Healthcare, BY Administration Route (USD Billion)
      1. 4.3.1 Intravenous
      2. 4.3.2 Intramuscular
      3. 4.3.3 Subcutaneous
      4. 4.3.4 Intraocular
      5. 4.3.5 Intracerebral
    4. 4.4 Healthcare, BY Region (USD Billion)
      1. 4.4.1 North America
        1. 4.4.1.1 US
        2. 4.4.1.2 Canada
      2. 4.4.2 Europe
        1. 4.4.2.1 Germany
        2. 4.4.2.2 UK
        3. 4.4.2.3 France
        4. 4.4.2.4 Russia
        5. 4.4.2.5 Italy
        6. 4.4.2.6 Spain
        7. 4.4.2.7 Rest of Europe
      3. 4.4.3 APAC
        1. 4.4.3.1 China
        2. 4.4.3.2 India
        3. 4.4.3.3 Japan
        4. 4.4.3.4 South Korea
        5. 4.4.3.5 Malaysia
        6. 4.4.3.6 Thailand
        7. 4.4.3.7 Indonesia
        8. 4.4.3.8 Rest of APAC
      4. 4.4.4 South America
        1. 4.4.4.1 Brazil
        2. 4.4.4.2 Mexico
        3. 4.4.4.3 Argentina
        4. 4.4.4.4 Rest of South America
      5. 4.4.5 MEA
        1. 4.4.5.1 GCC Countries
        2. 4.4.5.2 South Africa
        3. 4.4.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Spark Therapeutics (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bayer AG (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis AG (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 GSK (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Pfizer Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sarepta Therapeutics (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Astellas Pharma Inc. (JP)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 UniQure N.V. (NL)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY DISEASE TYPE
    4. 6.4 US MARKET ANALYSIS BY VECTOR SEROTYPE
    5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
    6. 6.6 CANADA MARKET ANALYSIS BY DISEASE TYPE
    7. 6.7 CANADA MARKET ANALYSIS BY VECTOR SEROTYPE
    8. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    9. 6.9 EUROPE MARKET ANALYSIS
    10. 6.10 GERMANY MARKET ANALYSIS BY DISEASE TYPE
    11. 6.11 GERMANY MARKET ANALYSIS BY VECTOR SEROTYPE
    12. 6.12 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    13. 6.13 UK MARKET ANALYSIS BY DISEASE TYPE
    14. 6.14 UK MARKET ANALYSIS BY VECTOR SEROTYPE
    15. 6.15 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
    16. 6.16 FRANCE MARKET ANALYSIS BY DISEASE TYPE
    17. 6.17 FRANCE MARKET ANALYSIS BY VECTOR SEROTYPE
    18. 6.18 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    19. 6.19 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
    20. 6.20 RUSSIA MARKET ANALYSIS BY VECTOR SEROTYPE
    21. 6.21 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    22. 6.22 ITALY MARKET ANALYSIS BY DISEASE TYPE
    23. 6.23 ITALY MARKET ANALYSIS BY VECTOR SEROTYPE
    24. 6.24 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
    25. 6.25 SPAIN MARKET ANALYSIS BY DISEASE TYPE
    26. 6.26 SPAIN MARKET ANALYSIS BY VECTOR SEROTYPE
    27. 6.27 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    28. 6.28 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
    29. 6.29 REST OF EUROPE MARKET ANALYSIS BY VECTOR SEROTYPE
    30. 6.30 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
    31. 6.31 APAC MARKET ANALYSIS
    32. 6.32 CHINA MARKET ANALYSIS BY DISEASE TYPE
    33. 6.33 CHINA MARKET ANALYSIS BY VECTOR SEROTYPE
    34. 6.34 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    35. 6.35 INDIA MARKET ANALYSIS BY DISEASE TYPE
    36. 6.36 INDIA MARKET ANALYSIS BY VECTOR SEROTYPE
    37. 6.37 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    38. 6.38 JAPAN MARKET ANALYSIS BY DISEASE TYPE
    39. 6.39 JAPAN MARKET ANALYSIS BY VECTOR SEROTYPE
    40. 6.40 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
    41. 6.41 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
    42. 6.42 SOUTH KOREA MARKET ANALYSIS BY VECTOR SEROTYPE
    43. 6.43 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    44. 6.44 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
    45. 6.45 MALAYSIA MARKET ANALYSIS BY VECTOR SEROTYPE
    46. 6.46 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    47. 6.47 THAILAND MARKET ANALYSIS BY DISEASE TYPE
    48. 6.48 THAILAND MARKET ANALYSIS BY VECTOR SEROTYPE
    49. 6.49 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
    50. 6.50 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
    51. 6.51 INDONESIA MARKET ANALYSIS BY VECTOR SEROTYPE
    52. 6.52 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    53. 6.53 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
    54. 6.54 REST OF APAC MARKET ANALYSIS BY VECTOR SEROTYPE
    55. 6.55 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
    56. 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. 6.57 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
    58. 6.58 BRAZIL MARKET ANALYSIS BY VECTOR SEROTYPE
    59. 6.59 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
    60. 6.60 MEXICO MARKET ANALYSIS BY DISEASE TYPE
    61. 6.61 MEXICO MARKET ANALYSIS BY VECTOR SEROTYPE
    62. 6.62 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
    63. 6.63 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
    64. 6.64 ARGENTINA MARKET ANALYSIS BY VECTOR SEROTYPE
    65. 6.65 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
    67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR SEROTYPE
    68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    69. 6.69 MEA MARKET ANALYSIS
    70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
    71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY VECTOR SEROTYPE
    72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
    73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
    74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY VECTOR SEROTYPE
    75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    76. 6.76 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
    77. 6.77 REST OF MEA MARKET ANALYSIS BY VECTOR SEROTYPE
    78. 6.78 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
    79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. 6.80 RESEARCH PROCESS OF MRFR
    81. 6.81 DRO ANALYSIS OF HEALTHCARE
    82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. 6.85 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
    86. 6.86 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
    87. 6.87 HEALTHCARE, BY VECTOR SEROTYPE, 2024 (% SHARE)
    88. 6.88 HEALTHCARE, BY VECTOR SEROTYPE, 2024 TO 2035 (USD Billion)
    89. 6.89 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
    90. 6.90 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
    91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.3.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.4.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.5.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.6.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.7.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.8.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.9.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.10.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.11.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.12.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.13.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.14.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.15.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.16.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.17.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.18.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.19.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.20.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.21.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.22.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.23.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.24.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.25.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.26.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.27.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.28.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.29.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
      2. 7.30.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
      3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Adeno Associated Virus Aav Vector Based Gene Therapy Market Segmentation

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Disease Type (USD Billion, 2025-2035)

  • Hematological Malignancies
  • Neurological Disorders
  • Cardiovascular Diseases
  • Ophthalmic Diseases
  • Oncology

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Vector Serotype (USD Billion, 2025-2035)

  • AAV1
  • AAV2
  • AAV5
  • AAV6
  • AAV8
  • AAV9

Adeno Associated Virus Aav Vector Based Gene Therapy Market By Administration Route (USD Billion, 2025-2035)

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Intraocular
  • Intracerebral

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.